Work

Mesenchymal stem cells for acute lung injury: Preclinical evidence

Year: 2010

Type: article

Abstract: Several experimental studies have suggested that mesenchymal stem cells may have value for the treatment of clinical disorders, including myocardial infarction, diabetes, acute renal failure, sepsis, and acute lung injury. In preclinical studies, mesenchymal stem cells have been effective in reducing lung injury from endotoxin, live bacteria, bleomycin, and hyperoxia. In some studies, the cultured medium from mesenchymal stem cells has been as effective as the mesenchymal stem cells themselves. Several paracrine mediators that can mediate the effect of mesenchymal stem cells have been identified, including interleukin-10, interleukin-1ra, keratinocyte growth factor, and prostaglandin E2. Further preclinical studies are needed, as is planning for clinical trials for acute lung injury.

Source: Critical Care Medicine

DOI: 10.1097/ccm.0b013e3181f1ff1d

Authors: Michael A. Matthay, Arnaud Goolaerts, James P. Howard, Jae Woo Lee

Institutions: Inserm, University of California, San Francisco, National Heart, Lung, and Blood Institute, University of California San Francisco Medical Center

Language: English

Topic: Mesenchymal stem cell research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Marie Curie, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development